Home | Medical-Newswire.Com:
(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.
On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.
The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,
"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."
Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.
It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."
First, let's revisit the problem of antibiotic resistance.
When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.
The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."
Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.
This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.
That's where NovaBay comes into the picture.
NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.
The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.
There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.
That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.
Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.
CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.
In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.
Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.
Shares slumped badly after that news hit the presses and have only barely recovered since.
On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.
Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.
A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.
Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.
The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.
A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.
Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.
Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.
By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.
If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.
For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?
Prices quickly quadrupled.
NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.
As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.
Disclosure: Long NBY.
For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance
Contact VFC's Stock House: firstname.lastname@example.org
VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.
For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com
Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse
'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213
For full disclaimer visit: http://vfcsstockhouse.com
VFC's Stock House
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on
top health stories.
G7 told to act on antibiotics as dreaded superbug hits U.S.
27 May 2016 at 8:39am
By Kylie MacLellan and Ben Hirschler ISE-SHIMA, Japan/LONDON (Reuters) - Britain told the G7 industrial powers on Friday to do more to fight killer superbugs as the United States reported the first case in the country of a patient with bacteria resistant to a last-resort antibiotic. U.S. scientists said the infection in a 49-year-old Pennsylvania woman "heralds the emergence of truly pan-drug resistant bacteria" because it could not be controlled even by colistin, an antibiotic reserved for "nightmare" bugs. In Japan, British Prime Minister David Cameron said leading countries needed to tackle resistance by reducing the use of antibiotics and rewarding drug companies for developing new medicines.
NIH experts question fed study linking cell phones to tumors
27 May 2016 at 8:31am
WASHINGTON (AP) ? National Institutes of Health expert reviewers are finding flaws in the agency's new study that connects heavy cell phone radiation to a slight increase in brain tumors in male rats.
GSK gets EU approval for first gene therapy for children
27 May 2016 at 8:15am
The world's first life-saving gene therapy for children, developed by GlaxoSmithKline and Italian scientists, was approved for sale in Europe on Friday, in a step forward for the pioneering technology to fix faulty genes. Called Strimvelis, it is designed for a tiny number of children with ADA Severe Combined Immune Deficiency (ADA-SCID). Strimvelis is the second gene therapy to be approved in Europe, after UniQure's Glybera, which treats a rare adult blood disorder.
Dr. Heimlich, 96, saves choking woman with namesake maneuver
27 May 2016 at 8:14am
Heimlich, who in multiple national television appearances had demonstrated the "Heimlich Maneuver" to dislodge food from an airway, had never employed it in an emergency, said spokesman Ken Paley. "After three compressions, this piece of meat came out, and she just started breathing, her whole face changed," Heimlich said in a video interview shared by Paley, vice president of marketing for Episcopal Retirement Services, which operates Deupree House.
Thai queen undergoes medical tests, palace says in rare statement
27 May 2016 at 7:53am
Thailand's 83-year-old Queen Sirikit has undergone medical tests and has "insufficient blood in the brain", the Royal Household Bureau said in a rare statement on her health on Friday. In a second statement late in the day, the palace said Queen Sirikit's medical tests were completed and yielded "satisfactory results". Queen Sirikit, who has seldom been seen in public in recent years, went for a health check on Wednesday, it said.
Ways Lifting Weights Will Change Your Life
27 May 2016 at 7:23am
Knowing that you are responsible for the results and you did it on your own is one of the perks of lifting weights.Click Here to see the Complete List of Ways Lifting Weights Will Change Your LifeOther than the obvious fact that lifting weights will increase your muscle strength and endurance, it also has numerous side effects that will change...
Rising Prescription Pricing Has Dire Consequences
27 May 2016 at 7:02am
Last week, the New York Times reported that a Florida man killed his sick wife of 50 years because he was unable to afford her medicine. While murder as a solution is uncommon, it is all too easy to find fixed income or retired seniors struggling to pay for necessary medications or not taking medicines as prescribed due to cost. The couple...
96-year-old Heimlich uses namesake maneuver on choking woman
27 May 2016 at 6:59am
CINCINNATI (AP) ? The 96-year-old Cincinnati surgeon credited with developing his namesake Heimlich maneuver recently used the emergency technique for the first time himself to save a woman choking on food at his senior living center.
Edible bug industry hopes crickets and kin are the next sushi
27 May 2016 at 6:22am
By Ben Klayman DETROIT (Reuters) - Just like raw tuna is a favorite of foodies everywhere, Robert Nathan Allen foresees a day when crickets will make their way onto consumers' plates. A growing need for more food sources as well as a desire to treat animals more humanely have proponents predicting entomophagy, or eating insects, will eventually spread more heavily to western and developed countries. "Sushi took 30, 40 years to really become a normal thing, but kale took like five years and kale's not even very tasty," said Allen, head of Austin, Texas-based Little Herds, a nonprofit founded to educate the public on the nutritional and environmental benefits of edible insects.
'Creative' stoners planted seed for safer medical marijuana: study
27 May 2016 at 6:02am
Swiss scientists have taken a leaf from the pothead recipe book to brew an e-cigarette cannabis liquid for medical use they said Thursday is safer than a joint and better than a pill. The team copied an improvised method popular among marijuana afficionados using butane gas to extract and concentrate cannabinoids -- the active, high-causing compounds of cannabis. "We were inspired by what is done illegally, underground, on the web fora," study co-author Vincent Varlet, a biochemist and toxicologist from the University Centre of Legal Medicine in Lausanne, Switzerland, told AFP.
EU regulators recommend approving Gilead's new hepatitis C drug
27 May 2016 at 5:06am
(Reuters) - Gilead Sciences Inc's new hepatitis C drug combination, which shares an active ingredient with blockbuster Sovaldi, was recommended for marketing approval by the European Medicines Agency. The EMA's Committee for Medicinal Products for Human Use said it recommended approval of the combination of sofosbuvir and velpatasvir. Sofosbuvir is at the center of a patent battle between Gilead and Merck & Co Inc. (http://bit.ly/20JOyWA) Sovaldi generated $1.28 bln of sales in the first quarter for Gilead. (Reporting by Rahul B in Bengaluru; Editing by Don Sebastian)
Roche boosted by early trial success with blood cancer drug
27 May 2016 at 4:56am
By Silke Koltrowitz and Ben Hirschler ZURICH/LONDON (Reuters) - Roche got a big boost on Friday when a clinical trial testing its new blood cancer drug Gazyva proved successful, lifting prospects for a medicine that will be pivotal as the Swiss company fights the threat of biosimilar competition. Investors had anticipated results of the study in 2017 but Roche was able to prove a clear benefit at the interim stage, implying the drug had a strong effect. The company is holding back detailed results until an upcoming medical meeting but it said Gazyva proved significantly better than its older drug Rituxan at delaying disease progression in people with previously untreated follicular lymphoma.
EU regulator's advisory panel backs AstraZeneca diabetes drug
27 May 2016 at 4:44am
(Reuters) - A panel that advises the European drugs regulator has supported an approval for AstraZeneca Plc's diabetes drug combination. The European Medicines Agency said on Friday that the Committee for Medicinal Products for Human Use backed AstraZeneca's combination of saxagliptin and dapagliflozin. The components of the combination are currently sold separately for the treatment of type 2 diabetes under the Onglyza and Farxiga brand names.
Hiroshima survivors: Obama speech moving, 'more than enough'
27 May 2016 at 4:26am
By Minami Funakoshi HIROSHIMA, Japan (Reuters) - Barack Obama, the first sitting U.S. president to visit Hiroshima, laid a wreath on Friday at the site of the world's first atomic bombing, which killed thousands instantly and about 140,000 within months. Following are comments from people in Hiroshima, which was devastated on Aug. 6, 1945. EIJI HATTORI, 73, SURVIVOR "I think (Obama's speech) was an apology." Hattori's parents and grandparents, who sold rice near where the bomb fell, all either died that day or in the years that followed.
High Risk for Breast Cancer May Be Normalized With Healthy Living, Study Finds
27 May 2016 at 4:23am
Researchers examined if lifestyle choice could change cancer risk in some women.